{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:32:09Z","timestamp":1772569929952,"version":"3.50.1"},"reference-count":17,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,8]]},"DOI":"10.2967\/jnumed.125.269655","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:00:33Z","timestamp":1749132033000},"page":"1239-1244","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, Safety, Blood Kinetics, and <sup>213<\/sup>Bi Distribution Studies of [<sup>225<\/sup>Ac]Ac-SibuDAB in Prostate Cancer Patients"],"prefix":"10.2967","volume":"66","author":[{"given":"Stefan","family":"Schmitl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Kretschmer-Chott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Patronas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Ritt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Weisbrod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Nics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Mitterhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025080106551269000_66.8.1239.1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR."},{"key":"2025080106551269000_66.8.1239.2","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1088\/1361-6560\/aa6a99","article-title":"Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies","volume":"62","author":"Robertson","year":"2017","journal-title":"Phys Med Biol."},{"key":"2025080106551269000_66.8.1239.3","first-page":"336","article-title":"Actinium-225 for targeted alpha therapy: coordination chemistry and current chelation approaches","volume":"33","author":"Thiele","year":"2018","journal-title":"Cancer Biother Radiopharm."},{"key":"2025080106551269000_66.8.1239.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"2025080106551269000_66.8.1239.5","doi-asserted-by":"crossref","unstructured":"Roscher M Bakos G Benesova M . Atomic nanogenerators in targeted alpha therapies: Curie\u2019s legacy in modern cancer management. Pharmaceuticals (Basel). 2020;13:76.","DOI":"10.3390\/ph13040076"},{"key":"2025080106551269000_66.8.1239.6","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025080106551269000_66.8.1239.7","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","article-title":"The in\u00a0vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier","volume":"9","author":"Kruijff","year":"2019","journal-title":"Sci Rep."},{"key":"2025080106551269000_66.8.1239.8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025080106551269000_66.8.1239.9","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/thno.40482","article-title":"Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity","volume":"10","author":"Deberle","year":"2020","journal-title":"Theranostics."},{"key":"2025080106551269000_66.8.1239.10","doi-asserted-by":"crossref","unstructured":"Busslinger SD Tschan VJ Richard OK Talip Z Schibli R M\u00fcller C . [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617. Cancers (Basel). 2022;14:5651.","DOI":"10.3390\/cancers14225651"},{"key":"2025080106551269000_66.8.1239.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05837-2"},{"key":"2025080106551269000_66.8.1239.12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","article-title":"Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy","volume":"19","author":"Borgna","year":"2022","journal-title":"Mol Pharm."},{"key":"2025080106551269000_66.8.1239.13","doi-asserted-by":"crossref","unstructured":"Ritt P Fernandez R Soza-Ried C . Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. February 3, 2025 [Epub ahead of print].","DOI":"10.1007\/s00259-025-07102-8"},{"key":"2025080106551269000_66.8.1239.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267206"},{"key":"2025080106551269000_66.8.1239.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"2025080106551269000_66.8.1239.16","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/3\/012"},{"key":"2025080106551269000_66.8.1239.17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy: how to deal with recoiling daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals (Basel)."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:55:31Z","timestamp":1754056531000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.2967\/jnumed.125.269655"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269655","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}